ACRS logo

ACRS
Aclaris Therapeutics Inc

4,942
Mkt Cap
$606.14M
Volume
244,842.00
52W High
$4.89
52W Low
$1.16
PE Ratio
-8.19
ACRS Fundamentals
Price
$4.36
Prev Close
$4.34
Open
$4.30
50D MA
$3.72
Beta
1.17
Avg. Volume
2.75M
EPS (Annual)
-$0.5297
P/B
5.07
Rev/Employee
$107,205.48
$280.28
Loading...
Loading...
News
all
press releases
Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus
Aclaris Therapeutics (NASDAQ:ACRS) provided a clinical program update on Tuesday, highlighting full top-line results from its phase I-A single-ascending dose (SAD) and multiple-ascending dose (MAD...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Aclaris Therapeutics (NASDAQ:ACRS) Major Shareholder Sells $1,359,000.00 in Stock
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) major shareholder Braden Michael Leonard sold 300,000 shares of Aclaris Therapeutics stock in a transaction on Thursday, April 23rd. The...
MarketBeat·3d ago
News Placeholder
Aclaris Therapeutics (NASDAQ:ACRS) Major Shareholder Braden Michael Leonard Sells 300,000 Shares
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) major shareholder Braden Michael Leonard sold 300,000 shares of the stock in a transaction on Thursday, April 23rd. The shares were sold at...
MarketBeat·4d ago
News Placeholder
Aclaris Therapeutics (NASDAQ:ACRS) Shares Gap Down - Here's What Happened
Aclaris Therapeutics (NASDAQ:ACRS) Shares Gap Down - Time to Sell...
MarketBeat·7d ago
News Placeholder
Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data Incoming
Aclaris Therapeutics (NASDAQ:ACRS) used an H.C. Wainwright inflammatory skin diseases conference fireside chat to outline development plans and differentiation points for its lead biologic candidate...
MarketBeat·17d ago
News Placeholder
Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Increases By 49.4%
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totaling 7,017,767 shares, an increase of 49.4% from the March 15th total of 4,697,214 shares. Based on an average...
MarketBeat·17d ago
News Placeholder
Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded shares of Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday...
MarketBeat·19d ago
News Placeholder
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Moderate Buy" by Analysts
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six analysts that are presently covering the company, Marketbeat reports...
MarketBeat·23d ago
News Placeholder
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Wall Street Zen
Wall Street Zen raised Aclaris Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·27d ago
News Placeholder
Aclaris Therapeutics (NASDAQ:ACRS) Trading Up 10.2% - What's Next?
Aclaris Therapeutics (NASDAQ:ACRS) Shares Up 10.2% - Time to Buy...
MarketBeat·30d ago
<
1
2
...
>

Latest ACRS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.